samedan logo
 
 
 
spacer
home > ebr > spring 2008 > twenty-first century recruits
PUBLICATIONS
European Biopharmaceutical Review

Twenty-First Century Recruits

Talent acquisition today poses numerous challenges and opportunities for the life sciences industry. Pete Leddy of Invitrogen explores the changing world of pharmaceutical recruitment

Recruiting and retaining top employees is critical in order to secure a company’s continued success. As the biotechnology industry grows and expands, its talent needs rapidly increase, while the pool of qualified, diverse applicants is shrinking. This article explores the overall environment for talent acquisition (TA) in the life sciences and discusses why a solid TA plan is essential to achieving business goals. It will focus on a few of the challenges and experiences faced by the industry over the next few years, and will outline the resources that companies have at their disposal to attract and retain top talent.

BUSINESS GOALS IN THE SHORT AND LONG TERM

In developing a talent acquisition plan, companies must examine both long- and short-term business goals in order to align any hiring with those goals. What must a company accomplish in order to grow? The answer to that question will evidently vary significantly from company to company. Biotechnology and pharmaceutical companies poised to enter the clinic must be adept at planning clinical trials and working with regulatory agencies such as the US Food and Drug Administration (FDA) or the European Medicines Agency (EMEA). On the other hand, biotechnology tools companies seeking to offer ever more advanced technologies to life sciences researchers must continue to invest in newer technologies and build strong infrastructures to meet the demands of their customers.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Pete Leddy is Senior Vice President of Human Resources for Invitrogen, where he oversees global HR strategy and manages all aspects of the field. Prior to joining Invitrogen in 2005, Pete served as Vice President of Human Resources for the Americas operations of Dell Incorporated. He holds a PhD and a Master of Science degree in Industrial Organizational Psychology from the Illinois Institute of Technology.
spacer
Pete Leddy
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

New laboratory and regulatory services for biotech customers

USA/Germany, September 21, 2020. Gerresheimer adds essential laboratory and regulatory services to its broad portfolio of products, solutions and services for biotech companies. Specialized laboratory technicians and an experienced team of further specialists offer these services in the two innovation and technology centers in Bünde (Germany) and Vineland (New Jersey/USA). Gx Biological Solutions offers full service for biotech companies regarding product development of primary packaging and drug delivery solutions, material and functional testing as well as comprehensive regulatory support. The partnership with Gerresheimer shortens the time to market for pharmaceutical companies, minimizes risks and saves resources.
More info >>

White Papers

Analysis of Biopharmaceuticals to Conform to ICHQ6B

RSSL

Worldwide, the pharmaceuticals market is anticipated to grow from more than USD 782 billion in 2011 to approach a value of just over USD 971 billion by the end of 2016, registering a CAGR of over 24%. In 2010 the average medicines expenditure per person within the UK was £271, and this is expected to increase with the ageing population. A significant and increasing proportion of these sales are protein-based biotherapeutics or biomolecules. Currently, these account for 19% of the total market, and are growing at twice the rate of traditional small molecule pharmaceuticals. It is predicted that close to 50% of the top 100 pharmaceutical products will be biomolecules by 2016. By far the largest segment of the biopharmaceutical market is the monoclonal antibody (MAb) with an estimated share of 25.6%, which corresponds to USD 51.1 billion.
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement